ANN ARBOR, Mich. — One-quarter of women who should take hormone-blocking therapies as partial of their breast cancer diagnosis possibly do not start or do not finish a five-year course, according to a new investigate led by University of Michigan Comprehensive Cancer Center researchers. Five years of daily tamoxifen or aromatase inhibitors — dual forms [...]
↧